Browsed by
Month: July 2012

Astrazeneca Compounds Target Topoisomerases in vivo

Astrazeneca Compounds Target Topoisomerases in vivo

Kinase inhibitors are an important class of anticancer and anti-inflammatory compounds. Pharmaceutical companies rely on structure activity-genotoxicity evaluations to evaluate off target action of novel drugs (such Ames or other in vitro genotoxicity screens). Effective drugs should be highly targeted and not pleiotropic. Researchers at AstraZeneca have recently shown that promising compounds (that hit the desired target and appear to be non-genotoxic) may target topoisomerases in vivo or show other DNA reactive characteristics. Off target drug action is extremely important…

Read More Read More